First MUSE Procedures For Treatment Of GERD Performed In Switzerland
OMER, ISRAEL (Mar 14, 2017) - Medigus Ltd. (NASDAQ: MDGS) (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced that the first MUSE procedures were performed in Switzerland by Prof. Dr. Gerhard Treiber at the Center for Digestive Diseases (Gastrozentrum) at Hirslanden Clinic in Aarau. It was reported that both procedures were successful and the patients were released from the hospital.
"I believe that the MUSE procedure will be beneficial for many of my patients suffering from long-term treatment of GERD," said Prof. Dr. Gerhard Treiber M.D./AGAF, Endoskopieabteilung (Endoscopy Unit), Center for Digestive Diseases (Gastrozentrum) at Hirslanden Clinic. "The procedures were efficient, and my patients were pleased with the incisionless approach, leading to potential reduced recovery time when compared to alternative options."
The MUSE system is a single-use flexible transoral stapler that merges the latest advancements in microvisual, ultrasonic and surgical stapling. The device comes equipped with an ultrasonic sight and range finder and a micro ScoutCam™ CMOS camera, which enables a single physician to perform an incisionless transoral fundoplication -- the procedure intended to treat the anatomical cause of gastroesophageal reflux disease (GERD).
"We are excited that MUSE is now being offered in Switzerland, expanding our availability in Europe," said Chris Rowland, Chief Executive Officer of Medigus. "Our minimally invasive solution for gastroesophageal reflux disease (GERD) can help reduce the unmet treatment need for patients who fall within the gap between drug therapy and invasive surgical procedures."